Drug prescribing patterns in Parkinson's disease: A pharmacoepidemiological survey in a cohort of ambulatory patients

Pharmacoepidemiology and Drug Safety

Volumn 11, Issue 2, 2002, Pages 149-157

  Leoni, Olivia ^a   Martignoni, Emilia ^a   Cosentino, Marco ^a   Michielotto, Donatella ^b   Calandrella, Daniela ^c   Zangaglia, Roberta ^d   Riboldazzi, Giulio ^e   Oria, Cristina ^e   Lecchini, Sergio ^f   Nappi, Giuseppe ^f   Frigo, Gianmario ^f  

^a DIVISION OF REPRODUCTIVE BIOLOGY   (United States)

^b UNIVERSITY OF LONDON   (United Kingdom)

^c RESEARCH AND DEVELOPMENT   (Australia)

^d College of Chemistry and Molecular Engineering ^*  (China)

^e UNIVERSITY OF SHEFFIELD   (United Kingdom)

^f UNIVERSITY OF INSUBRIA   (Italy)

Author keywords

Comorbidity; Drug indications; Drug prescribing; Idiopathic parkinson's disease

Indexed keywords

AMANTADINE; ANTIPARKINSON AGENT; ANXIOLYTIC AGENT; APOMORPHINE; BIPERIDEN; BORNAPRINE; BROMOCRIPTINE; CHOLINERGIC RECEPTOR BLOCKING AGENT; DIHYDROERGOCRYPTINE; DOPAMINE RECEPTOR STIMULATING AGENT; HYPNOTIC AGENT; LEVODOPA; LISURIDE; METIXENE; PERGOLIDE; PRAMIPEXOLE; ROPINIROLE; SEDATIVE AGENT; SELEGILINE; TOLCAPONE; TRIHEXYPHENIDYL;

ADULT; AGED; AMBULATORY CARE; ARTICLE; CARDIOVASCULAR DISEASE; COHORT ANALYSIS; COMORBIDITY; CONTROLLED STUDY; DEMOGRAPHY; DIGESTIVE SYSTEM DISEASE; DISEASE COURSE; DISEASE SEVERITY; DRUG FORMULATION; DRUG INDICATION; DRUG INFORMATION; DRUG USE; FEMALE; HEALTH SERVICE; HEALTH STATUS; HUMAN; IDIOPATHIC DISEASE; MAJOR CLINICAL STUDY; MALE; MEDICAL RESEARCH; MENTAL DISEASE; MUSCULOSKELETAL DISEASE; ONSET AGE; PARKINSON DISEASE; PHARMACOEPIDEMIOLOGY; PRESCRIPTION; PRIORITY JOURNAL; SYMPTOMATOLOGY;

ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; ANTIPARKINSON AGENTS; CHOLINERGIC ANTAGONISTS; COHORT STUDIES; COMORBIDITY; CROSS-SECTIONAL STUDIES; DATA COLLECTION; DOPAMINE AGENTS; FEMALE; HUMANS; ITALY; LEVODOPA; MALE; MIDDLE AGED; PARKINSON DISEASE; PHARMACOEPIDEMIOLOGY; PRESCRIPTIONS, DRUG;

EID: 0036242272     PISSN: 10538569     EISSN: None     Source Type: Journal    
DOI: 10.1002/pds.682     Document Type: Article

References (50)

1. The impact of Parkinson's disease on health status, health expenditures, and productivity
2. Costs of drug treatment in Parkinson's disease
3. Parkinson's disease: Update on pharmacologic options to slow progression and treat symptoms
4. Health-Related Quality-of-Life measurement in patients with Parkinson's disease
5. Treatment of Parkinson's disease by cell transplantation
6. An algorithm (decision tree) for the management of Parkinson's disease: Treatment guidelines
7. Drug utilization patterns as indicators
8. A chronic disease score from automated pharmacy data
9. Replicating the chronic disease score (CDS) from automated pharmacy data
10. Medications and their monitoring in Parkinson's disease in Dunedin
11. Clinical findings, status of care, comprehensive quality of life, daily life therapy and treatment at home in patients with Parkinson's disease
12. A survey of antidepressant drug use in Parkinson's disease
13. Differences in drug prescribing patterns in elderly parkinsonian patients identified at hospital admission
14. The accuracy of the clinical diagnosis of Parkinson's disease: A clinicopathologic study of 100 cases
15. Parkinsonism: Onset, progression and mortality
16. Epidemiological assessment of levodopa use by populations
17. Comparison of utilization of Sinemet and Parkinson's disease mortality as surrogate indicators of Parkinson's disease in the United States
18. Estimate of parkinsonism prevalence through drug prescription histories in the Province of Rome, Italy
19. Treatment of early Parkinson's disease
20. Madopar Dispersible in the treatment of advanced Parkinson's disease
21. Medical treatment of levodopa-induced dyskinesias
22. Workshop IV: Drug treatment guidelines for the long-term management of Parkinson's disease
23. LIMPE-Lega Italiana per la lotta contro la malattia di Parknson, le sindromi extrapiramidali e le demenze. Linee Guida per il Trattamento della Malattia di Parkinson 2000
24. The early treatment of Parkinson's disease: Levodopa, dopamine agonists or both
25. Variability in patterns of drug usage
26. Reported current use of prescription drugs and some of its determinants among 35-to-65-year-old women in mid-Sweden: A population-based study
27. Geriatric drug use and adverse event reporting in 1990
28. Management of drug therapy in the elderly
29. Stroke and Parkinson's disease
30. Parkinson's disease: A test of the multifactorial etiologic hypothesis
31. Comorbidités neurologiques du parkinsonisme
32. Epidemiology of Parkinsonism: Incidence, classification, and mortality
33. Depression in Parkinson's disease
34. Treatment of behavioral disturbances in Parkinson's disease
35. Management of behavioral and psychiatric problems in Parkinson's disease
36. Prevalence and clinical correlates of psychotic symptoms in Parkinson disease. A community-based study
37. Range of neuropsychiatric disturbances in patients with Parkinson's disease
38. Sleep disorders, pain, and depression in Parkinson's disease
39. Psychological functioning in patients with Parkinson's disease
40. Retrospective study of selegiline-antidepressant drug interactions and a review of the literature
41. Managing the late complications of Parkinson's disease
42. A review of normal sleep and its disturbances in Parkinson's disease
43. A community-based study of sleep disorders in patients with Parkinson's disease
44. The nighttime problems of Parkinson's disease
45. Sleep disturbances in Parkinson's disease patients and spouses
46. The influence of patient and physician gender on prescription of psychotropic drugs
47. Analyses of use of tranquilizers and sleeping pills across five surveys of the same population (1985-1991): The relationship with gender, age and use of other substances